Predictors of poor prognosis in multiple sclerosis (MS) can include demographic and environmental factors, clinical factors, MRI observations, and biomarkers. Early initiation of appropriate therapy is key when personalizing treatment for relapsing-remitting multiple sclerosis (RRMS), as is having a plan to determine sub-optimal responders, approaches to switching or escalating therapy, and consideration of more aggressive therapies for patients with silent advanced disease or early signs of poor prognosis.
In this CMEOCast podcast, expert faculty discuss treatment initiation options, particularly high efficacy treatments versus escalation, as well as when switching therapies might be necessary and how to take patient- and medication-related issues into consideration.
At the end of this CME/CE activity, participants should be able to:
The following learning objectives pertain only to those requesting CNE or CPE credit:
Supported by an educational grant from Celgene Corporation.
Physicians, PAs, nurse practitioners, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Lublin reports that he receives research support from Actelion Pharmaceuticals; Biogen; Brainstorm Cell Therapeutics Inc; National Institutes of Health (NIH); National Multiple Sclerosis Society (NMSS); Novartis; and Sanofi. He has consulting agreements, serves on advisory boards, or Data and Safety Monitoring Board for Acorda Therapeutics; Actelion Pharmaceuticals/Janssen Pharmaceuticals, Inc.; Apitope; Brainstorm Cell Therapeutics Inc.; Atara Biotherapeutics, Inc.;Avotres; Biogen; EMD Serono, Inc; GW Pharmaceuticals; Immunic, Inc.; Innate Immunotherapeutics; Jazz Pharmaceuticals, Inc.; Mapi Pharma; MedDay Pharmaceuticals; MedImmune/ Viela Bio; Mylan; Novartis; Orion Biotechnology; Polpharma; Receptos, Inc./Celgene Corporation; Roche/Genentech, Inc.; Sanofi/Genzyme Corporation; Teva Pharmaceuticals; The Population Council, Inc. and TG Therapeutics. He is a speaker for Sanofi (non-promotional).
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-104-H01-P.
Call us at 877.CME.PROS (877.263.7767).